|
LABAs in Asthma Defended at AAAAI Meeting
MedPage Today By John Gever, Senior Editor, MedPage Today ORLANDO — Despite FDA statements to the contrary, there is no hard evidence that long-acting beta-agonist (LABA) drugs increase the risk of death or severe exacerbations in asthma patients when combined with … |
View full post on asthma – Google News